Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 7,251 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo group Clear all
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

NCT04899271
View directory record Official record
Conditions
New-onset Type 1 Diabetes
Interventions
Ladarixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 14, 2026, 5:50 PM EDT
Active, not recruiting Phase 2 Interventional Results available

RCT of CBD for Anxiety in Advanced Breast Cancer

NCT04482244
View directory record Official record
Conditions
Advanced Breast Cancer, Anxiety, CBD
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00869401
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
dasatinib, temozolomide, placebo, radiation therapy
Drug · Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
207
States / cities
Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Not applicable Interventional

Effects of Exercise in People With Tetraplegia

NCT01202019
View directory record Official record
Conditions
Spinal Cord Injury, Tetraplegia
Interventions
Circuit Resistance Training (CRT)
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 3 Interventional

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, 1.0 mg rasagiline mesylate, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 2 Interventional

Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04505436
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HM15211, Placebo of HM15211
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
48
States / cities
Huntsville, Alabama • Chandler, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 5:50 PM EDT
Terminated Phase 2 Interventional

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

NCT05655299
View directory record Official record
Conditions
Psoriasis
Interventions
VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

NCT04566601
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Anaheim, California • Temecula, California • Upland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072630
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

NCT00389064
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
66 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Fort Myers, Florida • Gainsville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

NCT02145234
View directory record Official record
Conditions
Healthy Adults
Interventions
BMS-986089, Placebo matching with BMS-986089
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Not applicable Interventional Results available

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

NCT00945334
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Neomycin, Placebo, Rifaximin
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 14, 2026, 5:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alcohol, Breast Cancer, and Metabolism

NCT07779967
View directory record Official record
Conditions
Alcohol Drinking, Ethanol Intoxication, Breastfeeding
Interventions
Low-alcohol level exposure, Breast-pumping time
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 14, 2026, 5:50 PM EDT
Terminated Phase 2 Interventional

Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment

NCT00083967
View directory record Official record
Conditions
Retinal Detachment
Interventions
denufosol tetrasodium (INS37217) Intravitreal Injection
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
33
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 14, 2026, 5:50 PM EDT
Recruiting Phase 2 Interventional

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT07214571
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Valerian on Sleep in Healthy Older Adults

NCT00097604
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Valerian root extract
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
55 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

NCT01053247
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 4 Interventional

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

NCT03325647
View directory record Official record
Conditions
Klinefelter Syndrome
Interventions
Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 90 Days · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

NCT02537938
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
NGP 555
Drug
Lead sponsor
NeuroGenetic Pharmaceuticals Inc
Industry
Eligibility
40 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 14, 2026, 5:50 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

NCT04642638
View directory record Official record
Conditions
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Interventions
INO-4800, CELLECTRA® 2000, Placebo
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
16
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

NCT04860830
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Anaheim, California • Culver City, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

NCT02966314
View directory record Official record
Conditions
Idiopathic Angioedema
Interventions
Omalizumab, Placebos
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

NCT01976104
View directory record Official record
Conditions
Thrombocytopenia Associated With Liver Disease
Interventions
avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 14, 2026, 5:50 PM EDT
Completed Phase 3 Interventional Results available

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03750552
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
23
States / cities
Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 14, 2026, 5:50 PM EDT